Key personnels at CGS-CIMB left original firm to join CIMB's new stockbroking arm. This includes Ivy Ng head of research as well as our good friend Walter Aw
The stock retreated from a high of 86 cents in February 2023, but the decline appears to be over as the stock has rebounded from the 61.8% Fibonacci retracement level. Both the Strength and Weakness Index (RSI) and the Average Divergence Index (MACD) show strong upward momentum. In my opinion, stronger top-line growth will be a near-term positive for Recreation & Leisure Company, which closes its accounts on June 30 every year, has been facing net losses between the third quarter of fiscal year 2021 and the fourth quarter of fiscal year 2022. However, the company successfully turned a profit in the first quarter of fiscal year 2023.
Revenue for FY2023 was RM532.1 million, an increase of 26.2% compared to FY2022. The increase in revenue was mainly due to increased sales of condoms and lubricants, especially in Asia and the America.
The easing of global logistics disruptions and stabilization of raw material prices will also help improve Karex's profitability during this period. As a result, core net profit increased to RM15.4 million in FY2023 (net loss of RM3.9 million in FY2022).
However, what is surprising is that after the company announced its fourth-quarter results, it announced an interim dividend of 0.5 cents per share (accounting for 50% of net profit per share). This sudden surprise exceeded market expectations.
We understand that from 2020 to mid-2022, the global condom market experienced a difficult period of sharp decline in sales.
Sales of major players in the condom industry have experienced double-digit declines in the past two years. This situation is mainly related to the impact of the COVID-19 pandemic, with lockdown measures limiting human interaction and affecting condom use.
However, according to recent reports in Chinese media, condom products have experienced strong consumer demand this year, especially from online platforms, as coronavirus pandemic controls are eased and social and economic activities gradually return to normal.
The company has also launched a new condom product and is currently seeking approval from the U.S. Food and Drug Administration (FDA). The new condom product uses a thin film plastic material, resulting in better temperature and a more realistic feel.
This improvement is expected to encourage people to switch to this new product. It is worth mentioning that the profit margin of this new product is significantly higher. You can study Condom 001.
On the other hand, raw material (natural rubber and latex) and freight prices continued to return to their original levels after the epidemic eased, and increased the company's profits.
Karex is exposed to foreign currency risk in sales and purchases involving U.S. dollars. The appreciation of the US dollar against the ringgit will have a positive overall impact on its revenue.
According to my estimation, every 10% appreciation of the US dollar against the ringgit may increase the company's net profit margin by a single-digit percentage. However, this does not take into account the company's foreign exchange hedges, which may mitigate the impact of currencies on its financial position. However, dollar loans used to support overseas operations may offset this effect to some extent.
Karex is a Malaysian condom manufacturing and sales company that also provides personal lubricants, sex toys, catheters, probe covers, HIV and pregnancy test kits, and other medical-related products.
The company operates in Africa, Asia, the America and Europe. It serves brand owners, governments, NGOs and retail buyers.
Conclusion:
Karex's net profit growth has been boosted by a surge in demand for condoms as pandemic restrictions ease and socioeconomic activities return to normal. Stable production costs have increased net profit margins.
Karex shares appear to have stopped falling, with strong technical indicators showing signs of recovery. If its stock price breaks out of the cloud resistance, it could be on track for a significant move higher.
The stock's recent decline may simply be because funds are waiting for FDA approval of new condoms. Once it gets FDA approval, this condom stock is expected to hit a new high.
Regardless, freight costs, soaring latex prices, and a sharp decline in condom sales are potential risks that could curb Karex's profits.
@xiaoeh, all glove counters are turning around. From negative earnings to positive earnings. Karex is following the gloves stocks. The 1st quarter results will be released next Monday. Expected target price is RM0.72.
Still manage to turn from -0.005 to +0.010 and closed at RM0.705. The AGM and 1st quarter results are on next Monday (27 Nov 2023). The target price still maintains at RM0.72.
By the end of the first half of the financial year 2024 (28 Feb 2024), the FDA (Food and Drug Administration) of US should have approved the new 001 condoms to be exported to US. The price of Karex will move north.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
Income
12,404 posts
Posted by Income > 2023-02-05 13:53 | Report Abuse
Mustang AhMoing often and causing his legs no power to push the brake. Wow!!!
https://www.facebook.com/reel/529504299158761?mibextid=0NULKw&fs=e&s=TIeQ9V